Serum markers of bone metabolism in multiple myeloma: Prognostic value of the carboxy-terminal telopeptide of type I collagen (ICTP)

British Journal of Haematology

Volumn 96, Issue 1, 1997, Pages 103-110

  Abildgaard, N ^a   Bentzen, S M ^a   Nielsen, J L ^a   Heickendorff, L ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

bone specific alkaline phosphatase; collagen derived peptides; multiple myeloma; osteocalcin; survival

Indexed keywords

ALKALINE PHOSPHATASE; BETA 2 MICROGLOBULIN; CALCIUM; COLLAGEN TYPE 1; OSTEOCALCIN;

ARTICLE; BLOOD LEVEL; BONE METABOLISM; CARBOXY TERMINAL SEQUENCE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PRIORITY JOURNAL; PROGNOSIS; SURVIVAL;

ADULT; AGED; ALKALINE PHOSPHATASE; BETA 2-MICROGLOBULIN; BIOLOGICAL MARKERS; BONE AND BONES; COLLAGEN; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOCALCIN; PEPTIDE FRAGMENTS; PEPTIDES; PROCOLLAGEN;

EID: 0031027328     PISSN: 00071048     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2141.1997.8672495.x     Document Type: Article

References (42)

1. Abildgaard, N., Nielsen, J.L. & Heickendorff, L. (1994) Connective tissue components in serum in multiple myeloma: analyses of propeptides of type I and type III procollagens, type I collagen telopeptide, and hyaluronan. American Journal of Hematology, 46, 173-178.
2. Anderson, K.C., Jones, R.M., Morimoto, C., Leavitt, P. & Barut, B.A. (1989) Response pattern of purified myeloma cells to hematopoietic groeth factors. Blood, 73, 1915-1924.
3. 2-microglobulin produce a simple and powerful myeloma staging system. Blood, 80, 733-737.
4. Bataille, R., Chappard, D. & Basle, M. (1995) Excessive bone resorption in human plasmacytomas: direct induction by tumour cells in vivo. British Journal of Haematology, 90, 721-724.
5. Bataille, R., Chappard, D., Marcelli, C. Dessauw, P., Sany, J., Baldet, P. & Alexandre, C. (1989a) Mechanisms of bone destruction in multiple myeloma: the importance of an unbalanced process in determining the severity of lytic bone disease. Journal of Clinical Oncology, 7, 1909-1914.
6. Bataille, R., Delmas, P.D., Chappard, D. & Sany. J. (1990) Abnormal serum bone gla protein levels in multiple myeloma: crucial role of bone formation and prognostic implications. Cancer, 66, 167-172.
7. Bataille, R., Delmas, P.D. & Sany, J. (1987) Serum bone gla protein in multiple myeloma. Cancer, 59, 329-334.
8. 2-microglobulin in multiple myeloma: optimal use for staging, prognosis and treatment: a prospective study of 160 patients. Blood, 63, 468-476.
9. Bataille, R., Jourdan, M., Zhang, X.G. & Klein, B. (1989b) Serum levels of interleukin 6, a potent myeloma-cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. Journal of Clinical Investigation, 84, 2008-2011.
10. Bentley, S.A., Alabaster, O. & Foidart, J.M. (1981) Collagen heterogeneity in normal human bone marrow. British Journal of Haematology, 48, 287-291,
11. Brixen, K., Nielsen, H.K., Eriksen, E.F., Charles, P. & Mosekilde, L. (1989) Efficacy of wheat germ lectin-precipitated alkaline phosphatase in serum as an estimator of bone mineralisation rate: comparison to serum total alkaline phosphatase and serum bone gla protein. Calcified Tissue International, 44, 93-98.
12. Carlsson, K., Ljunghall, S., Simonsson, B. & Smedmyr, B. (1992) Serum osteocalcin concentrations in patients with multiple myeloma - correlation with disease stage and survival. Journal of Internal Medicine, 231, 133-137.
13. Carter, A., Merchov, S., Silivan-Draxler, I. & Tatarsky, I. (1990) The role of interleukin-1 and tumour necrosis factor-alfa in human multiple myeloma. British Journal of Haematology, 74, 424-431.
14. Charles, P., Mosekilde, L., Risteli, L., Risteli, J. & Eriksen, E.F. (1994) Assessment of bone remodeling using biochemical indicators of type 1 collagen synthesis and degradation: relation to calcium kinetics. Bone and Mineral, 24, 81-94.
15. Cox, D.R. (1972) Regression models and life-tables (with discussion). Journal of the Royal Statistical Society B, 34, 187-220.
16. de Grooth, R., Kawilarang, E., Mieremet, R., Löwik, C. & Nijweide, P.J. (1995) Divergent differentiation of the haematopoietic stem cell line C2GM into osteoclast or macrophages. Calcified Tissue International, 56, 82.
17. Durie, B.G.M. & Salmon, D.E. (1975) A clinical staging system for multiple myeloma: correlation of measured myeloma cell mass with presenting clinical features, response to treatment and survival. Cancer, 36, 842-854.
18. 2-microglobulin in myeloma: a Southwest Oncology Group Study. Blood, 75, 823-830.
19. Elomaa, I., Virkkunen, P., Risteli, L. & Risteli, J. (1992) Serum concentration of the cross-linked carboxyterminal telopeptide of type I collagen (ICTP) is a useful prognostic indicator in multiple myeloma. British Journal of Cancer, 66, 337-341.
20. Eriksen, E.F., Charles, P., Melsen, F., Mosekilde, L., Risteli, L. & Risteli, J. (1995) Serum markers of type I collagen formation and degradation in metabolic bone disease: correlation to bone histomorphometry. Journal of Bone and Mineral Research, 8, 127-132.
21. Evans, C.E., Galasko, C.E. & Ward, C. (1989) Does mveioma secrete an osteoblast inhibiting factor? Journal of Bone and Joint Surgery, 71B, 288-290.
22. Gomez, B., Haugen, S. & Ardakani, S. (1994) Measurement of bone specific alkaline phosphatase activity in serum using a monoclonal antibody. Journal of Bone and Mineral Research, 9, 348.
23. Hasselbalch, H., Junker, P., Hørslev-Petersen, K., Lisse, I. & Bentsen, K.D. (1990) Procollagen type III aminoterminal propeptide in serum in idiopathic myelofibrosis and allied conditions: relation to disease activity and effect of chemotherapy. American Journal of Hematology, 33, 18-26.
24. Hjort, M., Westin, J., Dahl, I.M.S., Gimsing, P., Hippe, E., Holmberg, E., Lamvik, J., Nielsen, J.L., Löfvenberg, E., Palva, I.P., Rödjer, S., Talstad, I., Turesson, I., Wislöff, F. & Zador, G. (1996) Interferon-alfa-2B in addition to melphalan-prednisone for initial and maintenance treatment in multiple myeloma: a randomized nordic trial. Annals of Internal Medicine, 124, 212-222.
25. Kaplan, E.L. & Meier, P. (1958) Non-parametric estimation from incomplete observations. Journal of the American Statistical Society C, 53, 457-481.
26. Kawano, M., Yamamoto, I., Iwato, K., Tanaka, H., Asaoku, H., Tanabe, O., Ishikawa, H., Nobuyoshi, M., Ohmoto, Y., Hirai, Y. & Kuramoto, A. (1989) IL-1b rather than lymphotoxin as the major bone resorbing activator in human multiple myeloma. Blood, 73, 1646-1649.
27. Krzyzaniak, R.L., Buss, D.H., Cooper, M.P. & Well, H.B. (1988) Marrow fibrosis and multiple myeloma. American Journal of Clinical Pathology, 89, 63-68.
28. Lichtenstein, A., Berenson, J., Norman, D., Chang, M.P. & Carlile, A. (1989) Production of cytokines by marrow cells obtained from patients with mutiple myeloma. Blood, 74, 1266-1273.
29. Ludwig, H., Nachbauer, D.M., Fritz, E., Krainer, M. & Huber, H. (1991) Inlerleukin 6 is a prognostic factor in multiple myeloma. Blood, 77, 2794-2795.
30. Mantel, N. (1966) Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemotherapy Reports, 50, 163-170.
31. Melkko, J., Niemi, S., Risteli, L. & Risteli, J. (1990) Radioimmunoassay of the carboxyterminal propeptide of human type I procollagen. Clinical Chemistry, 36, 1328-1332.
32. Mundy, G.R., Raisz, L.G., Cooper, R.A., Schechter, G.P. & Salmon, S.E. (1974) Evidence for the secretion of an osleoclast stimulating factor in myeloma. New England Journal of Medicine, 291, 1041-1045.
33. Parfitt, A.M., Simon, L.S., Villanueva, A.R. & Krane, S.M. (1987) Procollagen I carboxyterminal extension peptide in serum as a marker of collagen biosynthesis in bone: correlation with iliac bone formation rates and comparison with total alkaline phosphatase. Journal of Bone and Mineral Research, 82, 3-32.
34. Risteli, J., Elomaa, I., Niemi, S., Novamo, A. & Risteli, L. (1995) Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type 1 collagen: a new serum marker of bone collagen degradation. Clinical Chemistry, 39, 635-640.
35. Risteli, J., Niemi, S., Trivedi, P., Maentausta, O., Mowat, A.P. & Risteli, L. (1988) Rapid equilibrium radioimmunoassay for the aminoterminal propeptide of human type III procollagen. Clinical Chemistry, 34, 715-718.
36. Roodman, G.D. (1992) Interleukin-6: an osteotropic factor? Journal of Bone and Mineral Research, 7, 475-478.
37. Taube, T., Beneton, M.N.C., McCloskey, E.V., Rogers, S., Greaves, M. & Kanis J.A. (1992a) Abnormal bone remodelling in patients with myelomatosis and normal biochemical indices of bone resorption. European Journal of Haematology, 49, 192-198.
38. Taube, T., Franssila, K., Risteli, L., Risteli, J. & Elomaa, I. (1992b) Monitoring of multiple myeloma and bone marrow fibrosis with aminoterminal propeptide of type III collagen (PIIINP), British Journal of Haematology, 82, 32-37.
39. Valentin-Opran, A., Charhon, S.A., Meunier, P.J., Edouard, C.M. Arlot, M.E. (1982) Quantitative histology of myeloma-induced bone changes. British Journal of Haematology, 52, 601-610.
40. Vacca, A., Ribatti, D., Roncalli, L., Ranieri, G., Serio, G., Silvestris, F. & Dammacco, F. (1994) Bone marrow angiogenesis and progression in multiple myeloma. British Journal of Haematology, 87, 503-508.
41. Williams, A.T., Shearer, M.J., Oyeyi, J., Aitchison, R.G., Newland, R.G. & Schey, S.A. (1993) Serum osteocalcin in the management of multiple myeloma. European Journal of Cancer, 29A, 140-142.
42. Zhang, X.G., Klein, B. & Bataille, R. (1989) Interleukin 6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood, 74, 11-13.